rupiya.io
⠋Loading...
0%
❯ Scanning sector trends...
Fabino Enterprises Ltd is a Drug Manufacturers - Specialty & Generic company listed on BSE. The page combines exchange quotes, financial statements, shareholding, filings, and news so investors can review the business in one place.
Fabino Enterprises Ltd makes money through Domestic formulations, Exports and regulated markets, Specialty or institutional sales in Drug Manufacturers - Specialty & Generic. Revenue quality depends on demand growth, margin discipline, balance-sheet strength, and the company's ability to defend its position within Pharma.
Create a free account to view momentum, moving averages, and delivery signals.
Upgrade to view volatility, drawdown, factor, and risk metrics.
| Period | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|
| Sales | ₹3 Cr | ₹21 Cr | ₹18 Cr |
| Expenses | ₹3 Cr | ₹21 Cr | ₹18 Cr |
| Operating Profit | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| OPM % | 0.9% | 0.6% | 0.6% |
| Other Income | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Profit Before Tax | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Tax | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| Net Profit | ₹0 Cr | ₹0 Cr | ₹0 Cr |
| EPS (₹) | 0.1 | 0.2 | 0.3 |
| Dividend Payout % | 0% | 0% | 0% |
| Quarter | Sep 2023 | Mar 2024 | Sep 2024 | Mar 2025 | Sep 2025 |
|---|---|---|---|---|---|
| Sales | ₹2 Cr | ₹13 Cr | ₹8 Cr | ₹4 Cr | |
| Expenses | ₹2 Cr | ₹13 Cr | ₹8 Cr | ₹4 Cr | |
| Operating Profit | ₹0 Cr | ₹0 Cr | ₹-0 Cr | ₹0 Cr | |
| OPM % | 0.9% | 0.9% | -0.1% | 0.7% | |
| Depreciation | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | |
| Interest | ₹0 Cr | ₹0 Cr | ₹0 Cr | ₹0 Cr | |
| Net Profit | ₹0 Cr | ₹0 Cr | ₹-0 Cr | ₹0 Cr | |
| EPS (₹) | 0.0 | 0.4 | -0.2 | 0.1 |
Register free to see 1 more quarter.
| Period | Mar 2024 | Mar 2025 | Sep 2025 | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Liabilities | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Equity Capital | ₹2 Cr | ₹2 Cr | ₹2 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Reserves | ₹2 Cr | ₹2 Cr | ₹2 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Borrowings | ₹0 Cr | ₹1 Cr | ₹2 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Liabilities | ₹1 Cr | ₹10 Cr | ₹12 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Liabilities | ₹5 Cr | ₹15 Cr | ₹18 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Assets | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Fixed Assets | ₹0 Cr | ₹0 Cr | ₹1 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Investments | ₹0 Cr | ₹0 Cr | ₹0 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Receivables | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Inventory | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Cash & Equivalents | — | — | — | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Other Assets | ₹5 Cr | ₹15 Cr | ₹17 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Total Assets | ₹5 Cr | ₹15 Cr | ₹18 Cr | ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| Period | Operating | Investing | Financing | Net Cash Flow |
|---|---|---|---|---|
| Mar 2024 | ₹-1 Cr | ₹-0 Cr | ₹0 Cr | — |
| Mar 2025 | ₹-1 Cr | ₹-0 Cr | ₹1 Cr | — |
No dividend history available.
No corporate actions recorded.
| Company | M.Cap | P/E | ROE | 1Y Return |
|---|---|---|---|---|
| Sun Pharmaceutical Industries Ltd | ₹4,51,075 Cr | 41.3 | 0.00% | +7.16% |
| Dr Reddys Laboratories Ltd | ₹1,11,310 Cr | 19.7 | +11.84% | +8.69% |
| Cipla Ltd | ₹1,15,638 Cr | 25.5 | +11.74% | -2.61% |
| Apollo Hospitals Enterprise Ltd | ₹1,16,201 Cr | 64.5 | 0.00% | +24.63% |
| Divis Laboratories Ltd | ₹1,79,486 Cr | 72.5 | 0.00% | +7.59% |
Create a free account to see institutional ownership snapshots.
Create a free account to view recent director and promoter trades.
Create a free account to view recent institutional deal activity.
Create a free account to view analyst estimate summaries.
Create a free account to view ESG risk and governance summaries.
Upgrade to view issuer ratings, instruments, outlooks, and rating history.
rupiya.io is for research and education only. Metrics shown are not investment advice. Validate with SEBI-regulated disclosures before acting.